CORC  > 中国医学科学院 北京协和医学院
Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
Song, Yuqin; Gao, Quanli; Zhang, Huilai; Fan, Lei; Zhou, Jianfeng; Zou, Dehui; Li, Wei; Yang, Haiyan; Liu, Ting; Wang, Quanshun
2018
卷号132
ISSN号0006-4971
DOI10.1182/blood-2018-99-117848
URL标识查看原文
收录类别SCIE
内容类型期刊论文
URI标识http://www.corc.org.cn/handle/1471x/6349062
专题中国医学科学院 北京协和医学院
推荐引用方式
GB/T 7714
Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study[J],2018,132.
APA Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2018).Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study.,132.
MLA Song, Yuqin,et al."Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study".132(2018).
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace